|
Feb 21
|
Incyte and Genesis collaborate on small-molecule medicines
|
|
Feb 20
|
Incyte and Genesis Therapeutics Announce Strategic AI-focused Research Collaboration
|
|
Feb 18
|
Incyte Stock Sees Relative Strength Rating Rise To 71
|
|
Feb 18
|
Incyte to Present at Upcoming Investor Conferences
|
|
Feb 17
|
3 US Stocks Estimated To Be 14.6% To 47.8% Below Intrinsic Value
|
|
Feb 11
|
Incyte Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags
|
|
Feb 11
|
Incyte Corp (INCY) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic Outlook
|
|
Feb 11
|
Q4 2024 Incyte Corp Earnings Call
|
|
Feb 10
|
S&P 500 Gains and Losses Today: Supermicro Stock Surges Ahead of Business Update
|
|
Feb 10
|
Incyte Reports 2024 Financial Results and Outlines 2025 Projections
|
|
Feb 10
|
Why Incyte (INCY) Shares Are Plunging Today
|
|
Feb 10
|
Incyte Stock Sinks as Sales Forecast for Key Drugs Falls Short
|
|
Feb 10
|
INCY's Q4 Earnings Miss Mark, Revenues Beat on Higher Product Sales
|
|
Feb 10
|
Incyte Q4 Earnings: EPS Miss, Strong Jakafi And Opzelura Sales, Says 2025 To Be Catalyst Rich Including 4 Launches
|
|
Feb 10
|
Incyte (INCY) Reports Q4 Earnings: What Key Metrics Have to Say
|
|
Feb 10
|
Incyte forecasts downbeat annual sales of skin disease drug, shares fall
|
|
Feb 10
|
Incyte (INCY) Q4 Earnings Miss Estimates
|
|
Feb 10
|
Incyte (NASDAQ:INCY) Posts Better-Than-Expected Sales In Q4
|
|
Feb 10
|
Incyte: Q4 Earnings Snapshot
|
|
Feb 10
|
Incyte Reports 2024 Fourth Quarter and Year-End Financial Results, Provides 2025 Financial Guidance and Highlights 2025 R&D Milestones
|